PCAN1 inhibitors belong to a category of chemical agents designed to selectively target and inhibit the activity of the protein known as PCAN1. The abbreviation PCAN1 stands for a specific protein that plays a role in various cellular processes. The inhibition of this protein involves the disruption of its function, which can affect the biological pathways where the protein is normally active. These inhibitors are characterized by their molecular architecture that allows them to bind with high specificity to the PCAN1 protein. The design of these inhibitors often involves a deep understanding of the protein's structure, especially the active site where the inhibitor molecule needs to attach to exert its action. This interaction between the inhibitor and the protein is typically the result of extensive research into the molecular dynamics and interactions that govern PCAN1's function and how it can be modulated by small molecules.
The development of PCAN1 inhibitors involves a complex interplay of chemistry, biology, and pharmacology. These compounds are synthesized through a series of chemical reactions that are carefully planned to produce a molecule with the desired properties. The synthesis process is often iterative, involving cycles of design, testing, and modification to optimize the interaction with PCAN1. In the laboratory, various analytical techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry are utilized to determine the structure and purity of the compounds. The inhibitors are also subjected to a range of assays to assess their binding efficiency and specificity to the PCAN1 protein. These studies help in understanding the mechanism of action at the molecular level, which is crucial for the further development of these chemical agents. The specificity of PCAN1 inhibitors is particularly important, as it defines the selectivity of the compound for the target protein without affecting other proteins, which is a key aspect in their characterization.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that attenuates the PI3K/AKT/mTOR pathway, leading to reduced PCAN1 phosphorylation and activation since PCAN1 is downstream of mTOR signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor that suppresses the PI3K/AKT pathway, decreasing PCAN1 activation as it relies on PI3K-mediated signaling for its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Another PI3K inhibitor that acts similarly to Wortmannin, reducing AKT phosphorylation and consequently downregulating PCAN1 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor that blocks the MAPK/ERK pathway, indirectly affecting PCAN1 activity as this pathway can modulate PCAN1 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that impedes the JNK signaling cascade, which can regulate PCAN1 activity through stress response modulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor, attenuating the p38-mediated signaling pathway that can influence PCAN1 activity, particularly during cellular stress response. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A Src family kinase inhibitor that affects various signaling pathways, including those that can modulate PCAN1 activation through cytoskeletal dynamics. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
An inhibitor of MEK1/2, preventing the activation of ERK1/2 in the MAPK pathway and thereby indirectly diminishing PCAN1 signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that can lead to the accumulation of ubiquitinated proteins, indirectly impacting PCAN1 activity through altered protein degradation pathways. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
A tyrosine kinase inhibitor targeting BCR-ABL, c-KIT, and PDGFR, which can indirectly affect PCAN1 by altering growth factor signaling pathways. | ||||||